Cost-effectiveness of exagamglogene autotemcel gene-edited therapy in patients with sickle cell disease with recurrent vaso-occlusive crises in the United States
Compared to SOC, exa-cel was projected to considerably reduce the number of VOCs, improve survival, and reduce disease-related costs in patients with SCD. Exa-cel was projected to be a cost-effective treatment option.
Authors
- Hongbo Yang (ORCID: https://orcid.org/0000-0003-2741-8418)
- Sushanth Jeyakumar
- Michael Gargano (ORCID: https://orcid.org/0000-0002-2157-3591)
- Foluso Joy Ogunsile (ORCID: https://orcid.org/0000-0003-3906-029X)
- Yang Xie (ORCID: https://orcid.org/0000-0001-6493-3115)
- Chuka Udeze
- Andrea Lopez
- Nanxin Li
Institutions
- University of Alabama at Birmingham (US)
- Vertex Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1080/13696998.2026.2624971
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00